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B cells are the precursors of antibody-secreting cells. Since the frequency of B  cells 
with receptors for a  particular antigen is low, polyclonal stimuli have been  used to 
study B  cell activation. These  stimuli include mitogens,  such  as lipopolysaccharide 
(LPS) 1, antibodies specific for surface immunoglobulin (sIg), and soluble factors from 
T  cells. The results of studies with polyclonal activators suggest that activation of B 
cells from adult mice occurs in two stages:  (a)  the induction of proliferation by anti- 
Ig and T  cell-derived B cell growth factor(s)  (BCGF)  (1-3), and (b) differentiation to 
Ig secretion by T  cell-derived differentiation factors (BCDF)  (4-8). Depending on the 
source of T  cell-derived factors, the induction of IgM secretion may require concom- 
itant cross-linking of Ig receptors by anti-Ig (7, 8) or can occur in the absence of anti- 
Ig  (8-11).  The  lymphokine(s)  in  T  cell  supernatants  (SN)  that  induces  B  cells to 
secrete IgM has been termed B cell differentiation factor(s) for IgM or BCDFu (8,  12). 
In addition to BCDF~, we have defined a  second lymphokine (BCDFy)  that  induces 
IgGa secretion by LPS-stimulated B  cells (13). 
In  the present  study we have  distinguished BCDF~,  BCDFv,  and  BCGF by their 
molecular weights, ability to activate neonatal B  cells, and presence or absence in a 
panel of T  cell SN.  Furthermore, we have Shown that BCDF~ and BCDFv stimulate 
B  cells from  both  neonatal  and  adult mice, whereas  BCGF acts only on  the  latter. 
This finding might partially explain the relative immunoincompetence of immature 
B cells. 
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ovalbumin;  PBL, peripheral  blood lymphocytes; PBS, phosphate-buffered  saline; RAMIg, rabbit anti- 
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Materials and Methods 
Animals.  Adult BALB/e or (C57BL/6 ×  DBA/2) F1 (BDF1) (Cumberland Farms, Clinton, 
TN) mice were used at 8-20 wk of age. Neonates were bred in our colony and were used at 5- 
17 d of age. 
BCLt  Tumor.  The  BCLa  tumor was  maintained by in vivo  passage  in  BALB/c  mice. 
Peripheral blood lymphocytes (PBL)  were prepared from mice that carried the tumor for at 
least 8 wk. 90% or greater of PBL were tumor cells as determined by the expression of the BCL~ 
idiotype (14). 
Antibodies.  Affinity-purified  rabbit antibodies against mouse Ig (RAMIg), # (Rap), y (Ray), 
and 6  (RaS)  heavy chains have been described  (14,  15). Goat anti-p and goat  anti'-8 were 
prepared using the same immunogens. Sera were affinity purified, absorbed, and assayed as 
described  (14). Goat  anti-ovalbumin was  prepared  by  immunizing a  goat  with  1  mg  of 
crystallized ovalbumin (OVA) in complete Freund's  adjuvant. The goat was boosted at intervals 
and bled, and the pooled serum was affinity purified on Sepharose-OVA. Two monoclonal 
anti-Thy-1 antibodies were used (14):  the mouse IgM~-anti-Thy-l.2 product of the HO-13.4 
hybridoma cells, obtained from the Cell Distribution Center of the Salk Institute, La Jolla, CA, 
and the rat IgG-anti-Thy-1 product of the HO-12.4 hybridoma cells, obtained from Dr. Noel 
Warner (Beeton Dickinson & Co., Palo Alto, CA). The rat anti-Lyt-  1 and anti-Lyt-2 hybridomas 
(16) were obtained from the Cell Distribution Center of the Salk Institute. The purification of 
the monoelonal anti-Lyt-1 and anti-Lyt-2 antibodies has been described previously (8). The 
rabbit antibodies were  coupled to  cyanogen-bromide-activated Sepharose-4B  as  previously 
described (17). 
Deletion of T Cells.  T cells were removed by treatment of normal spleen cells or BCLI PBL 
with monoclonal anti-Thy-1.2 (HO-13.4) and baby rabbit complement (C) (Pel-Freeze Biolog- 
icals,  Inc., Rogers, AR). Alternatively, cells  were  treated  with a  cocktail of rat  hybridoma 
antibodies directed against Thy-1 (HO-12.4), Lyt-1 (53.7.313), and Lyt-2 (52.6.72), followed by 
RaT and C, as described (8). 
Culture Conditions.  Normal B cells or BCLI PBL were cultured in flat-bottomed microtiter 
plates (Linbro Scientific Co.,  Hamden, CT) at 2-5 ×  l0  b cells/ml in Hepes-buffered RPMI 
1640  supplemented with  penicillin, streptomycin, and  gentamycin (10  pg/ml),  50  pM  2- 
mercaptoethanol, and 10% fetal calf serum (FCS)  (Grand Island Biological Co., Grand Island, 
NY). Cultures were incubated in an atmosphere of 83% N2, 10% CO2, 7% 02 at 37°C. 
Radioimmunoassay (RIA) for Secreted Ig.  SN  from  4-6-d euhures of stimulated cells  were 
assayed for the presence of secreted  IgM and IgG by a solid phase RIA as previously described 
(13,  18). Mierotiter plates  (Cooke  Engineering, Alexandria, VA)  were coated with affinity- 
purified RAMIg and  1%  FCS.  Secreted  IgM was  bound to the  RAMIg-coated plates and 
detected with [125I]Retp. IgG was  detected by using [12.SI]Ray. These reagents had negligible 
cross-reactivity  (<:1%) with  inappropriate heavy  chains or  light  chains.  For  quantitation, 
standard curves using purified (BCL~) IgM (p~) (19), MOPC-104E (p~) (Bionetics Laboratory 
Products, Litton Bionetics Inc., Kensington, MD), or mouse IgG (yKk) were included in each 
assay. 
BCDF~ Assay.  B cell differentiation to IgM secretion was induced by culturing BCL1 PBL 
or normal B cells at 5 ×  l0  s eells/ml for 4 d, alone or in the presence ofT cell SN (12). IgM 
secretion was then assessed by RIA. 
BCDF  7 Assay.  B cell differentiation to IgG secretion was induced as previously described 
(13). Briefly,  normal B cells were cultured at 2 ×  105/ml  in mierotiter plates with 20 pg/ml 
LPS (Salmonella typhosa; Difco Laboratories, Detroit, MI). After 24 h the appropriate concen- 
tration of T cell SN was added. After 6 d IgG secretion was assessed by RIA. 
BCGF Assay.  B cell growth factor activity was detected by a modification of the method 
described by Howard et al. (1, 2). Briefly, 2.5-5 ×  105 B cells/ml were cultured in the presence 
of anti-/.t or anti-6 bound to Sepharose. T  cell SN was added either immediately or after 24 h. 
On day 3, cultured cells were pulsed for 16 h with 1 ~Ci/culture [3H]thymidine, harvested, and 
counted. 
T Cell SAT 
T CELL LINES PK 7.1.1.A AND PK 7.1.2.  Secondary alloreactive AKR anti-C57BL/6 (B6) cells 
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(106/ml) in medium supplemented with rat spleen concanavalin A  (Con A) SN as a source of 
interleukin 2 (IL-2) (20). These cells have been maintained in culture for > 1.5 yr. The 7.1.2E8 
and 7.1.2C7  cells are clones obtained by limiting dilution cloning of 7.1.2. Lymphokine release 
was induced (after washing the cells in IL-2-free medium containing 2% FCS) by pulsing the 
cells for 3 h with 10/zg/ml Con A, washing, and culturing for 24 h in medium lacking both IL- 
2 and Con A. Cells were removed by centrifugation and the cell-free SN was filtered, aliquoted, 
and stored at -70~C. 
EL-4  TUMOR.  EL-4  SN  was  prepared  by  stimulating  106  cells/ml  of a  cloned  subline 
obtained from Dr. J. Farrar (National Institutes of Health) (21) with 20 nM phorbol myristate 
acetate (Sigma Chemical Co., St. Louis, MO). Cell-free SN were collected after 48 h, The SN 
was brought to 50% saturation with ammonium sulfate and the pellet was discarded. Lympho- 
kines were then  precipitated by bringing the  SN  to  85%  saturation  with  (NH4)2SO4.  The 
precipitate was dissolved in phosphate-buffered saline (PBS)  (t0-20% of the original culture 
medium volume), dialyzed, and stored at -70°C. 
B6.  The B6 cell line was obtained by fusion of the FS6.14.13.AG2.1 cell line with T  cells 
from spleen and lymph nodes of C57BL/10 mice as previously described (22).  Lymphokine- 
containing SN were obtained by culturing B6 cells at  106 cells/ml with 4/zg/ml Con A for 24 
h. SN containing c~-methylmannoside were tested along with control medium. 
GEL VILTRATION  ANALYSIS.  Gel filtration analysis was performed on a  1 ×  50-era column of 
Sephacryl-200 (S-200)  (Pharmacia Fine Chemicals, Piscataway, N  J). The sample of T  cell SN 
was applied (maximum volume of 1 ml) and the material was eluted in PBS. 0.8-1-ml fractions 
were collected and the column fractions were brought to 5% (vol/vol) with FCS. Fractions were 
filter sterilized and tested for lymphokine activity. 
Results 
Definition of T  Cell-derived B  Cell Growth and Differentiation Factors.  BCGF is defined 
as a  T  cell-derived lymphokine that sustains anti-Ig-induced proliferation of B  cells 
(1, 2). The proliferative response of B cells from adult mice to anti-Ig alone is optimal 
on  day  1 and  falls to background  levels by days 3-4 of culture.  In  the presence of 
BCGF, proliferation is sustained. Thus, the response is optimal on days 3-4 and is the 
same or greater than the response to anti-Ig alone at day 1. 
BCDF~ is defined as a  T  cell-derived lymphokine that  induces IgM secretion by 
either normal or neoplastic B cells (8). BCDFv is defined as a lymphokine that induces 
IgG1 secretion in LPS-stimulated B  cells (13).  SN were considered negative for each 
lymphokine if they exhibited <10%  of the  activity obtained with  the reference  SN 
7.1.1a. 
Presence of BCGF, BCDF~, or BCDF  v in T Cell SN.  We first attempted to distinguish 
among  BCGF, BCDF~ and BCDF  v by analyzing the SN  from  different T  cell lines 
and clones. Table I  shows that SN from some T  cell lines (e.g., SN from EL-4,  7.1.2 
E8, and 7.1. la) contain all three lymphokines, whereas others (SN from B6 and 7.1.2 
C7)  contain only one.  In addition, there was no correlation between  the activity of 
BCGF, BCDF~, and BCDFv in different SN  (data not shown). Taken together, these 
results suggest that the three lymphokine activities are carried by different molecules. 
Alternatively, SN lacking a  particular lymphokine activity contain another lympho- 
kine that suppresses the activity of the first lymphokine, so that the first lymphokine 
is  not  absent  but  rather  suppressed.  Distinguishing  between  these  possibilities will 
only be possible when the lymphokines and/or suppressor factors have been purified. 
Gel Filtration Analysis of BCGF, BCDF,, and BCDFy.  SN from 7.1.2 was analyzed by 
gel filtration on a  S-200 column,  1 ml of SN was chromatographed on a  1 ×  50-cm 
column.  0.8  ml-fractions were collected and immediately supplemented to 5%  (vol/ 
vol)  with  FCS.  Each  fraction was  filter sterilized and  assayed for lymphokines.  As PURE,  ISAKSON, KAPPLER, MARRACK, KRAMMER, AND  VITETTA  603 
TABLE I 
Lymphokines Present in SN  from Different T Cell Lines and Clones 
T cell source  Reference 
Lymphokines* 
BCGF  BCDF~  BCDFv 
7.1.2 E8  12, 20  +  +  + 
EL-4  1, 2  +  +  + 
7.1.1a  12,  13, 20  +  +  + 
7.1.2 C7  -  --  + 
B6  22  -  +  - 
* SN were classified as negative if they contained <10% of the activity of a 
reference SN (7.1. la). 
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Fio.  1.  Gel filtration separation of BCDF~, BCDFr, and BCGF.  1 ml of SN from Con A-activated 
7.i.2 cells was chromatographed on a S-200 column (1  ×  50 cm) at 4°C in PBS. 0.8-ml  fractions 
were collected  and immediately supplemented with FCS to a final concentration of 5% (vol/vol). 
Fractions were filter sterilized and assayed for BCDF, on BCLt ceils (top panel), BCDF  r on LPS- 
activated B  cells  (middle panel), or BCGF  activity on  anti-Ig-treated B cells  (lower  panel)  as 
detailed in Materials and Methods. Each fraction was tested at a final concentration of 10% (vol/ 
vol) in the BCDF~ and BCGF assays and at a  final concentration of 20% (vol/vol)  in the BCDF  r 
assay. Each assay was performed in duplicate and the experiments were repeated three times. 
shown  in  Fig.  1,  this  method  separated  BCDF~  from  BCGF  and  BCDF r  BCDF~ 
consistently eluted as two broad  peaks averaging 30,000  and  60,000  mol wt, respec- 
tively.  In  contrast,  BCDFr  and  BCGF  could  not  be  distinguished from  each  other 
since both  eluted  in  broad  peaks with apparent  tool wt  of <20,000.  Similar results 
were obtained with SN from EL-4 and  7.1. la  (data not shown). 
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experiments were pooled and retested for BCDF~ and BCDF~. As shown in Fig. 2, the 
pool of the fractions eluting at  30-60,000  mol wt  had  excellent BCDFu  activity  (A) 
and little or no BCDFy activity (B).  In contrast, the pool of the fractions eluting at 
<20,000 mol wt had BCDFv activity (B)  but no BCDF,  activity (A). Thus, BCDF,  is 
distinct from BCDFv. 
Effect  of BCGF on  Adult  and Neonatal  B  Cells.  Adult  B  cells  can  be  induced  to 
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Fro.  2.  Response of splenic B cells from adult mice to 7.1.2 SN separated by gel filtration on S- 
200. 7.1.2 SN was processed and tested as described in Fig. 1. Fractions eluting at 30-60,000  mol wt 
(O) and fractions eluting at <20,000  mol wt (O) were pooled separately.  The indicated volumes of 
each pool were assayed for BCDFa (A) or BCDF  v (B). An optimal concentration of unfractionated 
7.1 SN (2.5/tl/culture) was included in each assay (@). 
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Fso. 3.  Response of B cells from adult and neonatal mice to BCGF. Splenic B cells were prepared 
from either adult or 13-d-old BALB/c mice and cultured at (A) 2.5 ×  10S/'ml or (B) 5 ×  10S/el in 
the presence of control (O), anti-/x (O)  (adult  only), or anti-8 (ZX) antibodies coupled to Sepharose. 
SN from 7.1.1a was added at the indicated concentrations. After 3 d, cultures were pulsed with [~H] 
thymidine ([nH]TdR)  and harvested  16  h  later.  Results  are expressed  as  the mean~SD. These 
experiments were repeated eight times with neonatal mice ranging in age from 5 to 17 d and adult 
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proliferate  in  vitro  by treatment  with  anti-Ig  (17,  18,  23-27);  proliferation  can  be 
sustained by the addition of BCGF (1, 2). Because B cells from neonatal mice (<21 d 
old)  do  not  proliferate  in  the  presence  of anti-Ig  alone  (8,  26)  but  do  respond  to 
BCDF~ (8), we determined whether these cells could respond to BCGF. Fig. 3 shows 
a  typical response of adult B cells to a  BCGF-containing T  cell SN. It is of interest to 
note that anti-/~ and anti-8 antibodies were equally effective in rendering these B cells 
responsive to BCGF. In contrast, neither anti-# (data not shown) nor anti-&treated B 
cells  from  neonatal  mice  proliferated  in  response  to  BCGF.  Similar  results  were 
obtained by using B cells from 5-17-d-old mice, although B cells from mice that were 
28 d old behaved like adult B cells. This suggests that either (a) anti-Ig-treated B cells 
from neonatal  mice do not express receptors  for BCGF;  (b)  neonatal  B  cells  might 
express BCGF receptors and bind BCGF but fail to proliferate;  (c)  neonatal spleens 
contain  cells  that  suppress  the  BCGF  response;  or  (d)  neonatal  spleen  cells  lack 
accessory  cells  necessary  for  the  BCGF  response.  Although  it  is  not  possible  to 
distinguish between possibilities a and b, we have performed experiments that suggest 
that possibilities c and d are unlikely. Thus, mixtures of equal numbers of spleen cells 
from adult and neonatal mice give the same BCGF response as the adult spleen cells 
alone.  This  suggests  that  the  neonatal  B  cells  do not  contain  suppressor  cells  that 
suppress  the BCGF response and that accessory cells that might be absent  from the 
population of neonatal spleen cells (but present in the adult spleen) are not responsible 
for the failure of immature B cells to respond to BCGF. 
Some proliferation  was observed when B  cells from either adult  or neonatal  mice 
were  treated  with  T  cell  SN  alone  (in  the  absence  of anti-Ig).  This  response  was 
particularly pronounced when using spleen cells from neonatal mice. To determine if 
this  mitogenic response  to SN alone was due  to B  cells,  Ig  + cells were deleted  with 
anti-Ig and C  before culture. The removal of sIg  + cells did not change the mitogenic 
effect of T  cell SN alone (Table II). In contrast, the response to BCDF~ was reduced 
by at  least  80%  (data  not  shown).  This  indicates  that  B  ceils  had  been  effectively 
deleted  by  anti-Ig  and  C.  We  therefore  conclude  that  the  proliferative  response 
induced by SN alone is not due to B cells in the culture.  Since the 7.1  and EL-4 SN 
TABLE  II 
Mitogenic Response to 7.1.1a SN of Spleen Cells  from Neonatal Mice Is Not 
Due to B Cells 
Treatment  of cells*  Experiment  Additions of 
number  7.1.1a SN~  C  Anti-Ig + C 
[SH]TdR incorporation 
¢ptt/ 
1  -  882  492 
+  9,627  12,195 
2  -  656  687 
+  8,498  10,521 
* Cells were cultured at 2.5 X 105/ml (+ 7.1.1a SN) for 3 d, pulsed with [all] 
TdR, and harvested 16 h later. Data are mean counts per minute of  triplicate 
cultures of 105 input  cells. IgM secretion in  response to  7.1.1a SN was 
decreased by >80% following treatment with anti-Ig and C. 
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FIG, at.  Response of B cells  from adult and neonatal mice to BCDFu.  Splenic B cells  from adult 
and 13-d-old  BALB/c mice were cultured at 5 X 105/ml  with the indicated concentrations of 7.1.1 a 
SN  (&)  or  7.1.2  SN  (I)  for 4  d.  IgM secretion  was detected  by  RIA as  described  in  detail  in 
Materials and Methods. Experiments were repeated eight times. 
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FIG. 5.  BCDFv-mediated  induction  of IgG secretion  by  LPS-stimulated  B  cells  from adult  or 
neonatal mice.  Splenic B cells were prepared from adult or  15-d-old  BALB/c mice and cells were 
cultured  at  2.5  ×  10S/ml  with 20/zg/ml LPS and the indicated  concentration of 7.1.1a  SN.  IgG 
secretion was measured by RIA on day 6. Adult B cells  (C)); neonatal B cells  (0). Experiments were 
repeated three times. Neonatal mice ranged in age from 10 to 21  d. 
contain other lymphokines (such as CSF and MAF [20]),  background proliferation 
may be  due  to  the  effect of these  lymphokines on  other cells,  e.g.,  hematopoietic 
progenitor cells and monocytes. 
Response of B Cells  from Adult and Neonatal Mice to BCDF, and BCDFy.  In view of the 
failure  of neonatal  cells  to  respond  to  BCGF,  it  was  of particular  importance  to 
evaluate their response to BCDF. The data in Fig. 4 confirm previous results (8) and 
show the effect of increasing amounts of 7.1. la or 7.1.2 SN on IgM secretion by adult 
and neonatal B cells. Clearly, both BCDF~-containing SN induce IgM secretion by B 
cells from both adult and neonatal mice. The response of the neonatal B cells is ~25% 
of that obtained with adult B cells, which is consistent with the number of immuno- 
competent B cells  in spleens from neonatal mice. 
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cultured at low density in the presence of LPS and the effect of increasing concentra- 
tions of a BCDFy-eontaining SN (7.1. la) on IgG secretion was determined. As shown 
in Fig.  5, both adult  and neonatal  B  cells secrete IgG in  response to LPS and this 
response can be greatly enhanced  by BCDF  v. Similar results were obtained in three 
separate experiments using cells from 10-17-d-old mice. Surprisingly, neonatal B cells 
secreted ~50% as much IgG as adult  B cells even though there was no evidence for 
proliferation. These results suggest that, in the absence of growth, immature B cells 
are more responsive to BCDFy, i.e., that either a  higher percentage of the cells are 
induced to secrete IgG or the levels of IgG secreted per cell are higher. 
These results demonstrate that B cells from both adult and neonatal mice respond 
to  BCDF~  and  BCDF  v.  Neonatal  B  cells  do  so in  the  absence of BCGF-mediated 
proliferation. 
Discussion 
The data presented in this report suggest that BCGF, BCDF~, and BCDFy are three 
distinct lymphokines. This conclusion is based on three lines of evidence:  (a) Each of 
the three lymphokines is present in some T  cell SN but not others;  (b) gel filtration 
distinguishes BCDF~ (30-60,000 mol wt) from BCGF/BCDFy (<20,000 mol wt); and 
(c) BCGF and BCDF show different target cell activities. Thus, both immature and 
mature B cells respond to BCDF~ and BCDF  v. In contrast, B cells from neonatal mice 
are unresponsive to anti-Ig and BCGF, whereas adult  B cells are highly responsive. 
These observations support the notion that BCGF is distinct from both types of BCDF 
and  that  BCDF~  and  BCDF  v are  different  from  each  other.  The  biological  and 
biochemical properties of the three lymphokines are summarized in Table III. 
Several other T  cell-derived lymphokines that induce polyclonal B cell growth and 
differentiation have been described  (4,  5, 9-11,  27-37).  This family of lymphokines 
has been referred to as B cell stimulating factors (BCSF)  (34).  BCSF include T  cell 
replacing factor (TRF)  (4, 5), allogeneic effect factor (AEF)  (29, 30), BCGF (1, 2, 31, 
33), BCDF (8,  13), and B cell replication and maturation factors (BRMF)  (11). These 
factors are all  defined  by their  ability  to  induce  growth  and/or  differentiation  of 
normal or neoplastic B cells. The relationship of these lymphokines to one another is 
unknown. 
At least two lymphokines (AEF and TRF) that induce differentiation to IgM and 
IgG secretion  may be  different  from  BCDF.  In  contrast  to  BCDFy  (unpublished 
results), AEF exhibits H-2 restriction (35). However, since AEF has not been evaluated 
using LPS-stimulated cells, it is not possible to formally exclude the possibility that 
TABLE  III 
Properties of BCGF, BCDF~, and BCDFy 
Lymphokine  Biological activity  Target B cells  Apparent tool 
wt 
BCGF  Sustains  anti-Ig-induced prolifera-  Adult mice  <20,000 
tion 
BCDF~  Induces IgM secretion  Adult and neonatal mice  30-60,000 
BCDFy  Induces  IgGl  secretion  in  LPS-  Adult and neonatal mice  <20,000 
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BCDF  v and AEF are related. Since the 7.1 SN lacks conventional TRF (5, 20), BCGF, 
BCDF,, and BCDF~ must be different from TRF. 
Lymphokines that induce B cell proliferation include BCGF and BRMF. BCGF is 
defined by its ability to sustain the proliferation of anti-Ig (1, 2) or mitogen-stimulated 
(33)  B cells.  Other lymphokines that sustain replication of slowly dividing B cells in 
the absence of other signals  (e.g., anti-Ig)  may exist and may be different  from the 
BCGF as  defined  by others  (1,  2,  31,  33)  and  ourselves in  this  study.  BRMF  (11) 
induces both growth and maturation of B cells in the presence of histoincompatible 
adherent cells and antigen. However, maturation occurs in both resting B cells and B 
cell blasts, whereas growth occurs only in B cell blasts (11).  It is therefore possible that 
BRMF contains both BCGF and BCDF,. 
Two lymphokines that induce the secretion of isotypes other than IgM have been 
described:  (a) a  lymphokine that specifically binds to IgE and induces IgE secretion 
by antigen-activated B cells (37), and  (b) a  tymphokine that induces IgG1 secretion 
by sIgG-negative, LPS-stimulated B cells (BCDF  0  (13). The existence of T cell subsets 
that  induce  the secretion  of particular  isotypes  (38-40)  raises the  possibility of the 
existence of additional isotype-specific lymphokines for other classes and subclasses of 
Ig. Isotype switching in activated B cells may be directed by T  cell-derived lympho- 
kines. Analogous with the stimulation of T  cell growth by IL-2 (41), such class and 
subclass-specific BCDF may bind to specific receptors on B cells. 
Perhaps the most provocative finding in this paper is that anti-Ig alone as well as 
anti-Ig and BCGF induce proliferation of B cells from adult  but not neonatal mice, 
whereas both mature and immature B cells can secrete IgM and IgG in response to 
BCDF~ and BCDFv, respectively. One interpretation of these data is that anti-Ig has 
two functions:  (a) to induce a  limited proliferative response in adult B cells, and (b) 
to induce the appearance of receptors for BCGF in adult  but not  neonatal  B  cells. 
Whether  adult  B  cells  responsive  to  BCDF  require  a  signal  from sIg receptors  is 
presently unclear, since anti-Ig is not required for BCDF activity in vitro. It is possible, 
however, that  BCDF~ stimulates  B  cell  blasts that  have already been  activated  by 
antigen in vivo. This possibility is supported by data from Julius et al. (42), who have 
reported that T  cells induce polyclonal differentiation only in large, and not in resting, 
B  cells.  Terminal  differentiation  of resting  B  cells  requires  cross-linking  of sIg  in 
addition to a T  cell signal. We have also recently found that BCDF acts on large but 
not small B cells in the spleen (Layton et al., unpublished results). 
The inability of neonatal B cells to proliferate in response to anti-Ig and BCGF is 
consistent with their inability to proliferate in response to LPS despite the fact that 
LPS induces immature B cells to secrete all isotypes of Ig (43).  Neonatal B cells are 
relatively immunoincompetent to challenge with specific antigen.  Our results might 
partially explain  this  incompetence by suggesting  that  neonatal  B  cells  terminally 
differentiate  in  the  absence  of clonal  expansion,  and  thus  yield  a  poor  antibody 
response. The implications of these findings for the ease of susceptibility to tolerance 
induction  of immature as opposed to mature B cells (44, 45)  is unclear.  However, it 
is conceivable that terminal differentiation in the absence of ctonal expansion is one 
mechanism for putative B cell tolerance as originally suggested by Sterzl and Trnka 
(46). If this were the case, one might postulate the existence of a suppressor mechanism 
in adult bone marrow or neonatal spleen that prevents the in situ terminal differen- 
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central lymphoid tissues might lack BCDF-producing T cells. In this regard, a number 
of laboratories have described suppressor monoeytes in the bone marrow (47, 48) and 
neonatal spleen  (49)  that prevent antibody responses of normal B cells in vitro. It is 
possible that these suppressor cells exert their effect via the suppression of BCDF and 
prevent immature B cells from terminally differentiating. 
Summary 
In these studies we have determined the molecular weights of B cell growth factor 
(BCGF)  (<20,000),  and B cell differentiation factors (BCDF)  that  induce  immuno- 
globulin  M  (IgM)  secretion  (BCDF~)  (30-60,000)  and  IgG  secretion  (BCDFv) 
(<20,000).  Thus, the molecular weight of BCDFv is distinct  from that of BCGF and 
BCDFv; BCGF and BCDFv cannot be distinguished. In addition, BCGF, BCDFu, and 
BCDFy are distinguishable by their presence or absence in different supernatants from 
a  panel  of  mitogen-induced  T  cell  clones.  These  results  suggest  that  the  three 
lymphokines are different. This conclusion is supported by their differential biological 
effect on B cells from adult and neonatal mice. Thus, treatment with anti-Ig induces 
B cells from adult mice to proliferate and this proliferation is sustained by BCGF. In 
contrast, even in the presence of BCGF, anti-Ig does not induce B cells from neonatal 
mice to proliferate. However, BCDF~ and BCDF  v induce IgM and IgG secretion in B 
cells, respectively, from both adult and neonatal mice. Thus, mature B cells can both 
clonally expand and differentiate in response to anti-Ig, BCGF, and BCDF, whereas 
immature B cells can only differentiate. The poor response of neonatal B cells to anti- 
Ig and BCGF may partially explain the relative immunoincompetence of immature 
B cells. 
Note added in proof" W. Lernhardt et al. (Nature [Lond.],  1982,  300:355)  and M. Okada 
et  al.  (J.  Exp.  Med.,  I983,  157:583)  have  described  hybridomas  that  make either 
BCGF or BCDF, further supporting the notion that these are two different lympho- 
kines. Moreover, Mayer et al.  (J.  Exp.  Med.,  1982,  156:1860)  have recently described 
a BCDF~. 
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